Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

New or developing antihypertensive agents

R R Evans1, D J DiPette

  • 1College of Pharmacy, University of Illinois, Chicago, USA.

Current Opinion in Cardiology
|July 1, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Behavioral And Personality Expectations Associated With Status Positions.

Multivariate behavioral research·2016
Same author

Use of the Ribonuclease Protection Assay for the Analysis and Characterization of Target mRNAs.

Methods in molecular medicine·2011
Same author

Bradykinin and prostaglandin E₁ regulate calcitonin gene-related peptide expression in cultured rat sensory neurons.

Regulatory peptides·2010
Same author

Calcitonin gene-related peptide and substance P contribute to reduced blood pressure in sympathectomized rats.

American journal of physiology. Heart and circulatory physiology·2005
Same author

Role of sensory nervous system vasoactive peptides in hypertension.

Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas·2002
Same author

Role of calcitonin gene-related peptide and substance P in Dahl-salt hypertension.

Hypertension (Dallas, Tex. : 1979)·2001
Same journal

An integrative approach to patient selection for mitral transcatheter edge-to-edge repair in secondary mitral regurgitation.

Current opinion in cardiology·2026
Same journal

Rebooting blood vessel repair: implications of the SEMA-VR CardioLink-15 trial.

Current opinion in cardiology·2026
Same journal

Advancements in wearable technology for heart failure patients.

Current opinion in cardiology·2026
Same journal

Minimally invasive approaches to coronary artery bypass grafting: techniques, current evidence, and future directions.

Current opinion in cardiology·2026
Same journal

Advances in artificial intelligence for the evaluation of mitral regurgitation.

Current opinion in cardiology·2026
Same journal

Role of nutritional interventions to reduce cardiometabolic disease burden in the community.

Current opinion in cardiology·2026
See all related articles

Newer pharmacologic treatments for hypertension are being developed to combat this widespread health issue. This review covers recently approved and investigational drugs for managing high blood pressure.

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine
  • Drug Development

Background:

  • Hypertension remains a significant global health concern despite recent treatment advances.
  • Existing therapies have reduced mortality and morbidity but have limitations.
  • There is an ongoing need for novel and specific pharmacologic interventions.

Purpose of the Study:

  • To review recently approved pharmacologic agents for hypertension.
  • To discuss pharmacologic agents currently under clinical development for hypertension.
  • To provide an overview of emerging treatments for managing high blood pressure.

Main Methods:

  • Literature review of recently approved hypertension medications.
  • Analysis of clinical trial data for investigational hypertension drugs.

Related Experiment Videos

  • Synthesis of information on novel pharmacologic targets and mechanisms.

    • Main Results:

    • Several new drug classes and agents have been approved.
    • A pipeline of promising agents is in various stages of clinical development.
    • These agents offer potential for improved efficacy and targeted therapy.

    Conclusions:

    • The pipeline for hypertension pharmacotherapy is robust.
    • Emerging treatments may offer new options for difficult-to-control hypertension.
    • Continued research is vital for addressing the global burden of hypertension.